Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential

TSX:EDT - Post by User

Spectral Medical Inc > Spectral Medical content from Baxter Invester Day 2022

<< Previous

Bullboard Posts

Next >>

Comment by davikingon May 27, 2022 11:12am

180 Views

Post# 34712162

RE:Spectral Medical content from Baxter Invester Day 2022

VERY interesting: Near term launches! :

Sepsis Diagnostic
Endotoxin diagnostic that aids in sepsis risk assessment

and

PMX Sepsis Filter
Exclusive distribution in U.S. / Canada of PMX sepsis filter

Must be pretty confident that PMX is going to "pass the muster", to mention it as "Near Term"

Don't see how our SIMI/DIMI fits in since they have a "Recent Launch":
PrisMax 2
CRRT machine simplifying delivery of therapy with digital enablement and ECCO2R support

and a "Future Launch":
PrisMax 3
CRRT machine optimized for citrate